Tradestie Institutional Equity Comparison Engine

NTLA vs HRMY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HRMY Overall Edge

HRMY Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus HRMY at 5.6x Forward P/E and 22.2% operating margin (+12.3% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against HRMY sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HRMY
NTLA N/M vs HRMY 5.6x Fwd P/E
Growth & Margin Winner HRMY
Op Margin -826.0% vs 22.2% ยท YoY -48.0% vs +12.3%
Momentum & Technical Winner NTLA
1Y +15.3% vs -3.4% ยท 52W Pos 20% vs 41%
Options & Structure Winner HRMY
BREAKDOWN (78th %ile IV) vs CONSOLIDATION (4th %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
1M Return -12.43%
1Y Return +15.34%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
HRMY NASDAQ
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$33.13
-1.87% 1D
Market Cap $2.0B
1M Return -12.7%
1Y Return -3.38%
Forward P/E 5.6x
Unified AI Score
57.1 / 100 HOLD
Tech 56.0 Fund 63.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +15.34% HRMY -3.38% Spread: +18.72 pp (NTLA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NTLA Revenue HRMY Revenue NTLA Op. Margin HRMY Op. Margin Margin Edge
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M $10M -246.8% -2433.8% NTLA
FY2020 $60M $160M -235.5% 10.6% HRMY
FY2021 $30M $310M -810.4% 28.7% HRMY
FY2022 $50M $440M -879.0% 27.4% HRMY
FY2023 $40M $580M -1420.5% 33.0% HRMY
FY2024 $60M $710M -923.1% 26.7% HRMY
FY2025 $70M $870M -651.7% 24.0% HRMY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (0) vs HRMY (10)
Institutional Metric NTLA HRMY Criterion Row Winner
Market Capitalization Scale $1.5B $2.0B Larger Scale HRMY
Trailing P/E Ratio Valuation N/M 11.2x Lower Multiple HRMY
Forward P/E Ratio Valuation N/M 5.6x Lower Multiple HRMY
Revenue Growth (YoY) Growth -48.0% +12.3% Higher Growth HRMY
Operating Margin (TTM) Profitability -826.0% 22.2% Higher Margin HRMY
Net Profit Margin Profitability 0.0% 18.1% Higher Margin HRMY
Return on Equity (ROE) Capital Efficiency -62.6% 18.7% Higher ROE HRMY
52-Week Range Position Momentum 20% ($8โ€“$18) 41% ($26โ€“$43) Stronger Trend HRMY
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 0.60ฮฒ ยท 45% Vol Lower Realized Risk HRMY
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 57.1 / 100 (HOLD) Higher Composite HRMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs HRMY Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HRMY CONSOLIDATION
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live HRMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor HRMY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.